NEWS

PRESS RELEASES

NOVEMBER 25, 2024
Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
NOVEMBER 12, 2024
Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates
JULY 22, 2024
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology
APRIL 16, 2024
Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer
FEBRUARY 27, 2024
Vittoria Biotherapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer
DECEMBER 07, 2023
Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
NOVEMBER 29, 2023
Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting
NOVEMBER 14, 2023
Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies
Visit our LinkedIn page
CAR T-cell therapy
CAR T-cell therapy – Clinical Edge Issue 3
Read more
Inside next-gen platforms
Inside next-gen platforms for cell therapy manufacturing
Read more
Immunotherapy advancements in cancer
Immunotherapy advancements: transforming cancer treatment
Read more
CD5 deletion enhances T-cell therapies
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Read more
Nicholas Siciliano discusses the future of CAR-T
Insider insights: Vittoria CEO Nicholas Siciliano on the future of CAR-T
Read more